Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06052319
Other study ID # NOPRODPEA0001
Secondary ID NOPRODPEA0001
Status Recruiting
Phase
First received
Last updated
Start date November 29, 2023
Est. completion date July 15, 2024

Study information

Verified date April 2024
Source Janssen Scientific Affairs, LLC
Contact Study Contact
Phone 844-434-4210
Email Participate-In-This-Study@its.jnj.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The purpose of this study is to assess the engagement and usefulness of Care4Today® Connect CAD-PAD digital platform in participants with coronary artery disease or peripheral artery disease (CAD or PAD).


Recruitment information / eligibility

Status Recruiting
Enrollment 300
Est. completion date July 15, 2024
Est. primary completion date July 15, 2024
Accepts healthy volunteers No
Gender All
Age group 40 Years to 90 Years
Eligibility Inclusion Criteria: - Must have a diagnosis of CAD and or PAD, who are on therapy or about to initiate therapy - Own an iPhone or Android mobile device - Have an active email account - Must sign a participation agreement or informed consent form (ICF) allowing data collection in accordance with local requirements - Willing to download and use Care4Today (C4T) CAD-PAD application (app) Exclusion Criteria: - Any cardiovascular conditions (for example, recent stroke, high bleeding risk, severe heart failure) or non-cardiovascular condition deemed as poor prognosis by the investigator and which may percent a patient from completing the study - Unable to read or write the language used for the C4T (English, or Spanish if Spanish version is available) - Visual or hearing impairment or mental disability that would preclude independent app use - Patients currently using the C4T app prior to the signing of ICF

Study Design


Intervention

Device:
Care4Today® Connect CAD-PAD Mobile Application
Participants will not receive any drug intervention in this study. Participants will use Care 4Today® Connect CAD-PAD mobile application for 3 months. The study will assess participant engagement and usefulness.

Locations

Country Name City State
United States University of Colorado Anschutz Medical Campus Aurora Colorado
United States HCA Houston Healthcare Medical Center Houston Texas
United States HCA Florida Memorial Hospital Jacksonville Florida
United States University of Florida Health Jacksonville Jacksonville Florida
United States Rio Grande Regional Hospital McAllen Texas
United States The Kansas City Heart Rhythm Institute Overland Park Kansas

Sponsors (2)

Lead Sponsor Collaborator
Janssen Scientific Affairs, LLC HCA Research Institute, LLC

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of Participants Who use the Care4Today (C4T) Coronary Artery Disease-Peripheral Artery Disease (CAD-PAD) Application for at Least 10 Weeks During the 3-Month Study Period Percentage of participants (of those who onboarded the C4T CAD-PAD app) who use CAD-PAD the application for at least 10 weeks during the 3-month study period will be reported. The weekly app use is defined as using at least one component of the app once a week. Up to 3 months
Primary Percentage of Engaged Participants who Complete End of Study Survey with Satisfaction Response Score of Greater Than or Equal to (>=) 2 for at Least 3 Questions Percentage of engaged participants who complete end of study survey with satisfaction response score of >= 2 for at least 3 questions (out of 6 total questions) will be reported. Satisfaction survey consists of six questions in the end of study - each with 5 possible responses on a likert scale (1-5). The lowest possible response to any question is 1 =disagree and the highest possible response to any question is 5 = agree. Higher response on this scale represents more agreement or satisfaction. Up to 3 months
See also
  Status Clinical Trial Phase
Recruiting NCT05292079 - CAPTURER PMCF Study ( rEPIC04D )
Recruiting NCT05292014 - ANGIOLITE PMCF Study ( rEPIC04F )
Recruiting NCT05292118 - Navitian PMCF Study ( rEPIC04C )
Recruiting NCT05292092 - Essential Pro PMCF Study ( rEPIC04E )
Completed NCT05292105 - NC Xperience PMCF Study( rEPIC04B)
Terminated NCT01443754 - Hybrid Revascularisation by Combined Coronary Artery Bypass Graft (CABG) and PCI in Multivessel Coronary Disease N/A
Completed NCT01435031 - EXPERT CTO: Evaluation of the XIENCE PRIME™ LL and XIENCE Nano™ Everolimus Eluting Coronary Stent Coronary Stents, Performance, and Technique in Chronic Total Occlusions N/A
Completed NCT00783302 - Study in Subjects Suspected of Having CAD Undergoing VISIPAQUE-enhanced CCTA as Part of Their Routine Medical Care N/A
Completed NCT00543400 - Evaluation of M118 in Percutaneous Coronary Intervention (EMINENCE) Phase 2
Completed NCT05516784 - Impact of CYP2C19 Genotype-guided Clopidogrel and Ticagrelor Treatment on Platelet Function Test and Metabolomics Profile Phase 4
Completed NCT02873052 - MyoVista Measurements in Patients With Atherosclerosis and CAD
Terminated NCT02984891 - Optical Coherence Tomography (OCT) Intravascular Ultrasound (IVUS) Dual Imaging
Completed NCT05292144 - Xperience Pro PMCF Study
Completed NCT02554292 - Post Market Surveillance of SeQuent Please Neo With Scoring Balloon
Completed NCT00265525 - Evaluation of a Web-based Intervention to Promote Physical Activity in Patients With Heart Disease. Phase 3
Completed NCT03570697 - Imaging of Coronary Plaques in Participants Treated With Evolocumab Phase 3
Terminated NCT05508893 - Screening for Coronary Artery Disease USing Primary Evaluation With Coronary CTA in Aviation Medicine (SUSPECT) N/A
Completed NCT02341664 - Patient and Provider Assessment of Lipid Management Registry
Completed NCT02098772 - Phase III Study Comparing Two Methods of Cardioplegia in Aortic Valve Surgery Custodiol-N Versus Custodiol Phase 3
Recruiting NCT05617599 - SUPRAFLEX CRUZ PMCF Study ( rEpic05 )